--- title: "Pre-market hot trades in US stocks: Zhengye Biotechnology pre-market down 7.75%; AstraZeneca pre-market up 3.46%" type: "News" locale: "en" url: "https://longbridge.com/en/news/280754599.md" description: "Zhengye Biotechnology pre-market down 7.75%; AstraZeneca pre-market up 3.46%; Onconetix pre-market up 75.47%; GMEX Robotics pre-market up 35.54%; Globavend pre-market up 24.27%" datetime: "2026-03-27T08:42:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280754599.md) - [en](https://longbridge.com/en/news/280754599.md) - [zh-HK](https://longbridge.com/zh-HK/news/280754599.md) --- # Pre-market hot trades in US stocks: Zhengye Biotechnology pre-market down 7.75%; AstraZeneca pre-market up 3.46% **Pre-market Hot Trades in US Stocks** Zhengye Biotechnology is down 7.75% in pre-market trading. There has been no significant news recently; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no\_news AstraZeneca is up 3.46% in pre-market trading. Based on recent key news: 1. On March 27, AstraZeneca announced that its drug tocilizumab met its primary endpoints in two Phase III clinical trials, significantly reducing the risk of acute exacerbations of chronic obstructive pulmonary disease. This positive result boosted market confidence and drove the stock price up. Source: Reuters 2. On March 26, AstraZeneca's global CEO met with Jiangsu provincial leaders in Nanjing, stating that the company will continue to invest in the Chinese market, particularly in Jiangsu province. This deepening strategic cooperation is seen as an important step for the company's expansion in the Chinese market, further enhancing investor confidence. Source: People's Financial News 3. On March 24, AstraZeneca signed an agreement with the Guangzhou Economic and Technological Development Zone to plan the construction of a radioactive conjugate drug production base in Guangzhou. This move is viewed as a long-term investment commitment in the Chinese market, further driving positive stock performance. Source: Zhitong Finance, innovation in the pharmaceutical industry accelerates, market confidence strengthens. **Top Gainers in Pre-market US Stocks** Onconetix is up 75.47% in pre-market trading. Based on recent key news: 1. On March 25, Onconetix announced its participation in Ericsson's global first 6G trial demonstration. This move boosted market confidence in the company's technological capabilities, leading to a significant rise in stock price. 2. On March 18, Onconetix appointed David White as the new CEO and refreshed the board leadership. This personnel change is seen as a signal of the company's strategic adjustment, enhancing investor confidence. 3. On March 25, Onconetix amended its previous 8-K form to supplement David White's employment agreement. This move demonstrates transparency in corporate governance, further stabilizing market sentiment. The 6G technology trial has attracted market attention, and the industry's prospects are promising. GMEX Robotics is up 35.54% in pre-market trading. Based on recent key news: 1. On March 27, GMEX Robotics announced that its system aims to support hotel operations by reducing labor intensity while maintaining high-quality food preparation. This news may have boosted market confidence in the company's future growth, leading to a rise in stock price. 2. On March 27, GMEX Robotics director Wu Junye submitted documents to the U.S. Securities and Exchange Commission, reporting that he did not hold beneficial ownership of GMEX securities as of March 18. This disclosure may have alleviated market concerns about insider shareholding changes, further driving the stock price up On March 27th, Benzinga's stock ranking showed that GMEX's price trend is negative across all time frames. However, the current rise in stock price may reflect the market's reassessment of the company's future potential. Small-cap stocks are highly volatile and require cautious investment. Globavend, pre-market up 24.27%, has no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation ### Related Stocks - [ZYBT.US](https://longbridge.com/en/quote/ZYBT.US.md) - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) ## Related News & Research - [AstraZeneca Tracks Real-World Sinus Surgery Outcomes in China: What Investors Should Watch](https://longbridge.com/en/news/286132902.md) - [AstraZeneca's blood pressure drug wins U.S. approval](https://longbridge.com/en/news/286720674.md) - [AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios](https://longbridge.com/en/news/286801629.md) - [Owkin Expands AstraZeneca Collaboration Around K Pro AI Platform](https://longbridge.com/en/news/286291609.md) - [](https://longbridge.com/en/news/286807703.md)